Charles Calderaro III net worth and biography

Charles III Biography and Net Worth

Insider of Avidity Biosciences

Charles Calderaro III, Chief Technical Officer, joined Avidity Biosciences in January 2025. He has more than 35 years of experience in biotechnology, pharmaceutical, and cell and gene therapy company operations and in CMC drug development. Prior to joining Avidity, Mr. Calderaro served as Chief Technical Officer for Shoreline Biosciences, where he was responsible for advancing programs in oncology and autoimmune diseases and developing scalable bioprocesses for manufacturing gene editing and cell therapies. Prior to Shoreline, he served as Global Head of Technical Operations at Kite Pharma, a Gilead Company, and Senior Vice President, Global Manufacturing at BioMarin. In addition, he previously held roles of increasing responsibility during his 14-year tenure at Genentech, a member of the Roche Group, and at Aventis Behring LLC (now CSL Behring). Mr. Calderaro was also previously a commissioned officer in the U.S. Navy. He earned his M.B.A. from Texas Christian University, his M.S. in Nuclear Engineering from the U.S. Naval Nuclear Power School, and his B.S. in Electrical Engineering from the University of Notre Dame.

What is Charles Calderaro III's net worth?: The estimated net worth of Charles Calderaro III is at least $3.60 million as of January 7th, 2026. III owns 49,797 shares of Avidity Biosciences stock worth more than $3,602,813 as of January 12th. This net worth evaluation does not reflect any other assets that III may own. Learn More about Charles Calderaro III's net worth.
How do I contact Charles Calderaro III?: The corporate mailing address for III and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at [email protected]. Learn More on Charles Calderaro III's contact information.
Has Charles Calderaro III been buying or selling shares of Avidity Biosciences?: Within the last three months, Charles Calderaro III has sold $269,201.21 in shares of Avidity Biosciences stock. Most recently, Charles Calderaro III sold 3,727 shares of the business's stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $72.23, for a transaction totalling $269,201.21. Following the completion of the sale, the insider now directly owns 49,797 shares of the company's stock, valued at $3,596,837.31. Learn More on Charles Calderaro III's trading history.
Who are Avidity Biosciences' active insiders?: Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Kathleen Gallagher (Insider), Steven Hughes (Insider), Charles III (Insider), Arthur Levin (Insider), Michael MacLean (Chief Financial and Chief Business Officer), Teresa Mccarthy (Insider), John Moriarty, Jr. (Chief Legal Officer and Corporate Secretary), Eric Mosbrooker (Chief Commercial Officer), Tamar Thompson (Director), and Troy Wilson (Director). Learn More on Avidity Biosciences' active insiders.
Are insiders buying or selling shares of Avidity Biosciences?: During the last year, insiders at the biotechnology company sold shares 37 times. They sold a total of 706,819 shares worth more than $31,469,399.56. The most recent insider tranaction occured on January, 7th when CEO Sarah Boyce sold 8,576 shares worth more than $619,444.48. Insiders at Avidity Biosciences own 3.8% of the company. Learn More about insider trades at Avidity Biosciences.
Information on this page was last updated on 1/7/2026.

Charles Calderaro III Insider Trading History at Avidity Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/7/2026	Sell	3,727	$72.23	$269,201.21	49,797

Charles Calderaro III Buying and Selling Activity at Avidity Biosciences

Avidity Biosciences Company Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $72.35

$72.23

$72.37

50 Day Range

MA: $71.41

$69.78

$72.37

2 Week Range

Now: $72.35

$21.51

$72.61

Volume

1,521,453 shs

Average Volume

2,400,979 shs

Market Capitalization

$10.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95